Nature Communications · 2016 · 72 citations · 37 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCytokine-based TherapyImmune RegulationNatural Killer Cell BiologyNatural Killer Cell FunctionRegulatory T CellsNatural Killer Cell Receptor Nkg2dNatural Killer Cell-based Cancer ImmunotherapyNatural Regulatory T CellsNkg2 Receptor SignalingNkg2d-mediated RecognitionRecombinant Fusion ProteinsTargetingTumor Vasculature Targeting
Despite over 20 years of clinical use, IL-2 has not fulfilled expectations as a safe and effective form of tumour immunotherapy. Expression of the high affinity IL-2Rα chain on regulatory T cells mitigates the anti-tumour immune response and its expression on vascular endothelium is responsible for life threatening complications such as diffuse capillary leak and pulmonary oedema. Here we describe the development of a recombinant fusion protein comprised of a cowpox virus encoded NKG2D binding protein (OMCP) and a mutated form of IL-2 with poor affinity for IL-2Rα. This fusion protein (OMCP-mutIL-2) potently and selectively activates IL-2 signalling only on NKG2D-bearing cells, such as natural killer (NK) cells, without broadly activating IL-2Rα-bearing cells. OMCP-mutIL-2 provides superior tumour control in several mouse models of malignancy and is not limited by mouse strain-specific variability of NK function. In addition, OMCP-mutIL-2 lacks the toxicity and vascular complications associated with parental wild-type IL-2.
37
Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Onur Boyman, Marek Kovář, Mark P. Rubinstein et al. · Science · 2006 · 868 citations
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Aron M. Levin, D.L. Bates, Aaron M. Ring et al. · Nature · 2012 · 554 citations